NeoGenomics is trading 4.34% down at $18.30 in after-hours trading after closing at $19.13 on October 5, 2026; no reliable report directly attributes the decline to a specific event. - The company announced preliminary, unaudited third-quarter revenue of approximately $209 million and 28% year-over-year NGS revenue growth. - NeoGenomics reiterated full-year guidance and indicated it expected to raise the revenue outlook midpoint; the announcement does not establish why shares fell.